CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.65B, above the global median of $1.18B
- FinancialsAltman Z-Score 14.41: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.65BUSDvs all stocks (USD)
Trailing P/E
152.54xRevenue (TTM)
105.59MUSDvs all stocks (USD)
Profit Margin
12.02%Beta
0.9000xvs all stocks
52-Week Change
156.58%vs all stocks
Market Capitalization
1.65BUSDvs all stocks (USD)
Enterprise Value
1.70BUSDvs all stocks (USD)
Trailing P/E
152.54xForward P/E
23.06xPEG Ratio
-0.2933xPrice to Sales (TTM)
16.10xPrice to Book (MRQ)
36.12xEnterprise to Revenue
16.13xEnterprise to EBITDA
67.63xGross Margin
67.61%Profit Margin
12.02%Operating Margin
35.77%Return on Assets (TTM)
11.86%Return on Equity (TTM)
35.97%Revenue (TTM)
105.59MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.88USDUpdated Sep 27, 2026Quarterly Revenue Growth
98.60%Gross Profit (TTM)
64.85MUSDvs all stocks (USD)
EBITDA (TTM)
3.20MUSDvs all stocks (USD)
Net Income (TTM)
12.69MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
98.59%Operating Cash Flow (TTM)
15.13MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
6.58MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
79.95MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
37.21MUSDFY2025 · Dec 31, 2025Gross Profit
42.74MUSDFY2025 · Dec 31, 2025Operating Income
-844.00KUSDvs all stocks (USD)
Pre-tax Income
-4.56MUSDFY2025 · Dec 31, 2025Income Tax Expense
43.00KUSDFY2025 · Dec 31, 2025Net Income
-4.60MUSDFY2025 · Dec 31, 2025EBIT
-844.00KUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
3.20MUSDFY2025 · Dec 31, 2025Research & Development
7.76MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
35.82MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-4.60MUSDFY2025 · Dec 31, 2025Operating Cash Flow
8.44MUSDFY2025 · Dec 31, 2025Free Cash Flow
8.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
25.94MUSDFY2025 · Dec 31, 2025Income Tax Paid
118.00KUSDFY2025 · Dec 31, 2025Interest Paid
3.33MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-4.60MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
4.04MUSDFY2025 · Dec 31, 2025Stock-based Compensation
5.51MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.83MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.40MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.81MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.76MUSDFY2025 · Dec 31, 2025Capital Expenditures
-333.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-333.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
28.29MSharesUpdated Sep 27, 2026Float Shares
22.30MSharesUpdated Sep 27, 2026Shares Short
1.54MSharesUpdated Sep 27, 2026Short Ratio
2.70daysvs all stocks
Short % of Shares Outstanding
7.46%vs all stocks
% Held by Insiders
4.87%vs all stocks
% Held by Institutions
70.58%vs all stocks
Total Cash (MRQ)
26.84MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.9390USDUpdated Sep 27, 2026Total Debt (MRQ)
29.23MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6273xCurrent Ratio (MRQ)
1.52xBook Value per Share (MRQ)
1.65USDUpdated Sep 27, 2026Total Assets
92.11MUSDvs all stocks (USD)
Total Current Assets
60.58MUSDFY2025 · Dec 31, 2025Total Liabilities
65.96MUSDFY2025 · Dec 31, 2025Total Non-current Assets
31.53MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
27.47MUSDFY2025 · Dec 31, 2025Total Current Liabilities
38.49MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
25.94MUSDFY2025 · Dec 31, 2025Accounts Receivable
11.76MUSDFY2025 · Dec 31, 2025Inventory
15.42MUSDFY2025 · Dec 31, 2025Accounts Payable
10.98MUSDFY2025 · Dec 31, 2025Short-term Debt
8.79MUSDFY2025 · Dec 31, 2025Long-term Debt
22.23MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
5.24MUSDFY2025 · Dec 31, 2025Common Stock (Book)
27.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-112.49MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
26.15MUSDvs all stocks (USD)
52-Week Low
14.27USDUpdated Sep 27, 202652-Week High
66.37USDUpdated Sep 27, 202652-Week Change
156.58%vs all stocks
Beta
0.9000xvs all stocks
50-Day MA
52.94USDUpdated Sep 27, 2026200-Day MA
30.93USDUpdated Sep 27, 2026Avg 10-Day Volume
474.24KSharesUpdated Sep 27, 2026Avg 30-Day Volume
618.21KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
0.3900USDUpdated Sep 27, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Cash Flow, Profit, and Revenue All Growing
Free cash flow and gross profit have both grown over four years, with revenue up in each of the last three.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 14.41: safe zoneNotable
Altman Z-Score: 14.41
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.65B, above the global median of $1.18BNotable
Market cap (USD): 1,648,675,226Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Intellia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Cheezheng Tibetan Medicine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qingdao Haier Biomedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nolato AB
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GH Research plc
Tier 1ProductionApproval-Gated PipelineRule
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule